Detalhe da pesquisa
1.
A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.
Neoplasia
; 23(9): 929-938, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34329950